When to Use BioFire in the Blood Culture Workflow
BioFire (FilmArray BCID2) should be performed immediately upon blood culture bottle signaling positive, as part of a rapid diagnostic testing protocol integrated with active antimicrobial stewardship program (ASP) support. 1
Optimal Implementation Strategy
Timing of Testing
- Run BCID2 as soon as the blood culture bottle flags positive - this is when the test provides maximum clinical benefit by accelerating time to targeted therapy 2, 3
- The test delivers results in <2 hours from positive bottle, compared to 24-48 hours for conventional identification and susceptibility testing 1
- Studies show median time to targeted therapy improves from 24.2 hours (conventional) to 17.0 hours (with BCID2), representing approximately 1 day, 5 hours, and 35 minutes faster results 2, 4
Critical Success Factors
Active ASP integration is non-negotiable for clinical benefit. The 2025 ASM guidelines emphasize that rapid results become meaningless without timely communication to providers 1. Implementation requires:
- Real-time communication protocols: Phone calls, text pages, or digital alerts to providers when actionable results are available 1
- ASP team review and recommendations based on BCID2 results, with antimicrobial modifications occurring in approximately 28.8% of cases 2
- 24/7 availability maximizes impact: Studies show mortality reduction only during hours when testing was available (weekday daytime), with no benefit in overall populations when testing was limited 3
When NOT to Run BCID2
Do not test bottles with likely contaminants - this wastes approximately 19.5% of reagent costs on negative results 5. Pre-analytical stewardship should:
- Minimize skin contaminant testing through proper blood culture collection technique 1
- Consider clinical context before reflexively testing every positive bottle
- Establish protocols for when repeat testing is indicated 1
Important Caveats and Pitfalls
Off-Panel Pathogens
12-19.5% of positive blood cultures contain organisms not on the BCID2 panel 2, 5. A negative BCID2 result requires nuanced interpretation:
- Does NOT rule out bloodstream infection
- Conventional culture identification remains essential
- Clinical decisions must incorporate the patient's overall context 2
Polymicrobial Infections
Concordance drops to 77.5-79% in polymicrobial samples 5, 6. Key challenges:
- Resistance genes cannot be definitively attributed to a specific co-detected organism 5
- May require multicolony subculture for accurate identification 7
- ΔCp analysis (difference in crossing point values) can help identify discrepancies, particularly with CoNS 7
False Positives
Candida species show substantial false-positive rates, particularly C. tropicalis (often detected alongside C. parapsilosis) 8. This stems from:
- Non-viable DNA fragments in blood culture media
- Cross-reactivity in sensitive PCR analysis
- Requires microbiological expertise for interpretation 8
Resistance Gene Detection
While resistance genes are detected in 93.4% of matched specimens 6, the qualitative-only output limits clinical utility:
- Cannot quantify organism burden
- In polymicrobial samples, cannot definitively link resistance gene to specific pathogen 5
- mecA/C, CTX-M, and KPC are most frequently detected 5
Cost-Effectiveness Considerations
At approximately €250 per test 5, diagnostic stewardship is essential:
- Target testing to patients with sepsis/septic shock where rapid de-escalation or escalation is critical 4
- Avoid reflexive testing of all positive bottles
- Monitor post-analytical actionability - results without action represent wasted costs 1
The mortality benefit (adjusted OR 0.50-0.58) is only realized when testing is continuously available and integrated with active ASP support 2, 3. Without these elements, BCID2 implementation shows no clinical benefit despite the expense.